Druniler (Febuxostat)

Druniler is marketed in the European Union; regulatory approval status in other regions, including the United States, may differ and should be verified with local health authorities.

Febuxostat can be administered with or without food; taking it consistently with the same routine may help maintain stable absorption.

Serum uric acid levels are typically checked before starting therapy and periodically thereafter, often every 2–4 weeks initially, to assess treatment response.

If a dose is missed, the patient should take it as soon as remembered unless it is close to the time of the next scheduled dose; they should not double the dose.

Dose adjustment may be necessary for patients with moderate to severe renal impairment; clinicians should evaluate renal function before prescribing.

Febuxostat is not primarily a cardiovascular drug, but rare serious cardiovascular events have been reported; patients with existing heart disease should be monitored.

The safety of febuxostat during pregnancy or lactation has not been established; it should only be used if the potential benefit justifies the potential risk.

Patients are advised to limit purine‑rich foods, reduce alcohol intake, stay hydrated, and maintain a healthy weight to support uric acid control.

High‑dose aspirin and certain herbal supplements that influence uric acid metabolism may interfere with febuxostat efficacy and should be discussed with a healthcare provider.

Uric acid reductions are often observed within a few weeks of consistent therapy, but full therapeutic effect may require several months.

Symptoms such as rash, blistering, swelling of the face or throat, or difficulty breathing require immediate medical attention as they may indicate a severe hypersensitivity reaction.